Компания vTv Therapeutics анонсировала участие в инвестиционных конференциях в сентябре 2026 года

Руководство биотехнологической компании vTv Therapeutics объявило о своем участии в двух ключевых инвесторских мероприятиях в Нью-Йорке в сентябре 2026 года. В ходе встреч топ-менеджмент обсудит перспективы клинических исследований кадисеглиатина — нового перорального препарата для лечения диабета 1 типа.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September: H.C. Wainwright 28th Annual Global Investment Conference Format: Fireside Chat and one-on-one investor meetings Date: Wednesday, September 16, 2026 Time: 10:00-10:30 AM ET Location: New York, NY 5th Annual ROTH Healthcare Opportunities Conference Format: One-on-one investor meetings Date: Tuesday, September 29, 2026 About vTv Therapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn. About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated. Investor Contact John Fraunces LifeSci Advisors, LLC 917-355-2395 Media Contact Caren Begun TellMed Strategies 201-396-8551